Literature DB >> 10673993

The costs of managing patients with advanced colorectal cancer in 10 different European centres.

N Neymark1, I Adriaenssen.   

Abstract

With the aim of estimating and comparing the direct hospital costs of managing patients with advanced colorectal cancer in various countries, data on resource utilisation and unit prices were collected. Data on the consumption of medical resources were collected by a retrospective examination of the hospital charts for 20 patients in each of 10 centres in five European countries. To make cost comparisons meaningful, a complete and consistent set of unit prices for all the medical resources used in each of the countries would be required, but this could not be achieved. As an alternative method of comparison, the most complete set of unit prices (from Belgium) was used here to estimate the imputed average total cost of patient management in each centre. By using this approach, a summary index was created, which reflected only differences in resource utilisation. This index showed that there were considerable differences in the amounts of resources used for treating these patients, between, as well as within, countries. Differences of the same order of magnitude were found, when the treatment of subgroups of patients, according to site and stage of disease, were examined.

Entities:  

Mesh:

Year:  1999        PMID: 10673993     DOI: 10.1016/s0959-8049(99)00216-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Cost of care for colorectal cancer in Ireland: a health care payer perspective.

Authors:  L Tilson; L Sharp; C Usher; C Walsh; Whyte S; A O'Ceilleachair; C Stuart; B Mehigan; M John Kennedy; P Tappenden; J Chilcott; A Staines; H Comber; M Barry
Journal:  Eur J Health Econ       Date:  2011-06-03

Review 2.  Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.

Authors:  Pasquale Comella; Rossana Casaretti; Claudia Sandomenico; Antonio Avallone; Luca Franco
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Authors:  Niels Neymark; Thierry Gorlia; Ines Adriaenssen; Benoit Baron; Martine Piccart
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.

Authors:  Jacqueline Müller-Nordhorn; Heike Englert; Karl Wegscheider; Hendrike Berger; Frank Sonntag; Heinz Völler; Wolfgang Meyer-Sabellek; Thomas Reinhold; Eberhard Windler; Hugo A Katus; Stefan N Willich
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

5.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

Review 6.  Cost considerations in the treatment of colorectal cancer.

Authors:  Frank G A Jansman; Maarten J Postma; Jacobus R B J Brouwers
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

7.  Provider Costs of Treating Colorectal Cancer in Government Hospital of Malaysia.

Authors:  Meram Azzani; Maznah Dahlui; Wan Zamaniah Wan Ishak; April Camilla Roslani; Tin Tin Su
Journal:  Malays J Med Sci       Date:  2019-02-28

8.  Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?

Authors:  G Brown; S Davies; G T Williams; M W Bourne; R G Newcombe; A G Radcliffe; J Blethyn; N S Dallimore; B I Rees; C J Phillips; T S Maughan
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.